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17β-Estradiol induced LPA1 receptor desensitization in C9 cells stably expressing LPA1 receptors and transiently expressing estrogen receptor α.
Such desensitization was evidenced by a reduction in lysophosphatidic acid-mediated Ca2+mobilization and it was associated to receptor phos-
phorylation and internalization. These effects of 17β-estradiol were rapid (taking place over 5min) andwere blocked by the estrogen receptor antagonist
ICI 182780. Similarly, inhibitors of phosphoinositide 3-kinase (wortmannin and LY294002) and of protein kinase C (staurosporine and Gö 6976)
blocked 17β-estradiol-induced LPA1 receptor desensitization and phosphorylation. Confocal microscopy evidenced LPA1 receptor internalization in
response to 17β-estradiol treatment. Association between LPA1 receptors and protein kinase C α was suggested by co-immunoprecipitation assays.
Protein kinase Cαwas associatedwith LPA1 receptors in the absence of stimulus and such association further increased in a dynamic fashion in response
to 17β-estradiol. The results demonstrated that in C9 cells estrogens modulate LPA1 action through estrogen receptor αwith the participation of protein
kinase C α and phosphoinositide 3-kinase.
© 2007 Elsevier B.V. All rights reserved.Keywords: LPA1 receptor; PKC; PI3K; 17-b estradiol; ERa; GPCR1. Introduction
LPA (lysophosphatidic acid) was originally reported as one
of the major growth factors in mammalian serum [1,2], and it is
now recognized as an extracellular lipid mediator with a great
variety of actions in diverse cell types. LPA is a potent inducer
of cytoskeletal remodeling and cell migration, and a promoter of
cell survival and proliferation [1,3–5].
This remarkable diversity of responses is explained by the fact
that LPA action occurs via a large family of G protein-coupled
receptors (GPCRs) with multiple downstream effectors. To date,
five functional LPA receptors have been identified in mice and
humans [6,7]: LPA1 [8,9], LPA2 [10], LPA3 [11], LPA4 [12,13]
and LPA5 [14,15]. Genetic deletion studies in mice have shown⁎ Corresponding author. Tel.: +52 5622 5603; fax: +52 5616 2282.
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doi:10.1016/j.bbamcr.2007.11.014their essential biological functions [16–20]. LPA receptors have
important participation in processes such as development, im-
plantation and embryo spacing [20], organization of brain archi-
tecture and function [16,21], and initiation of neuropathic pain
[22], among others. While essential roles for individual receptors
have been observed, it has been somewhat surprising that more
profound effects such as early embryonic lethality have not been
observed in single or even double receptor knock-outs [17], in
contrast with results of deletion studies for the key LPA bio-
synthetic enzyme, autotaxin, which produces embryonic lethality
[18]. Functional redundancy of receptor subtypes likely explains
such a paradox.
GPCR function is regulated by means of many different
processes with different time frames. Receptor phosphorylation
appears to be a cardinal initial event in the desensitization of
these receptors and occurs mainly on serine and threonine
residues located in the receptor's third cytoplasmic loop and/or
C-terminal tail [23,24]. Receptor phosphorylation increases
their affinity for a family of cytoplasmic proteins, known as
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receptor interaction [26]. In addition, arrestins act as adapters
facilitating clathrin coated pit-mediated receptor endocytosis
[26–30]. Internalized receptors are ultimately dephosphory-
lated by membrane-associated phosphatases [31,32], recycled
back to the plasma membrane, or ubiquitin-targeted for
degradation. Several lines of evidence support the hypothesis
that receptor internalization is also required for resensitization
[27,28,30,33].
Two major types of desensitization exist: homologous, and
heterologous. Homologous desensitization, in which receptors
occupied by agonists reduce their responsiveness, mainly in-
volves receptor phosphorylation by G protein-coupled receptor
kinases. Heterologous desensitization is induced by agents
pharmacologically unrelated with the target, and mainly in-
volves phosphorylation of receptors and other signaling entities
by second messenger-activated kinases, such as protein kinase
A and protein kinase C (PKC) [27,34–36].
Estrogen receptors (ERs) are nuclear transcription factors,
which, when bound to agonists such as 17-β estradiol (E2),
modulate gene transcription. There are two estrogen receptor
isoforms, these arising from different genes: ERα, and ERβ
[37,38]. Despite the clarity with which ERs have been shown to
act as transcription factors, many studies support the notion that
not all biological effects of estrogens are accomplished via
regulation of gene expression [39,40]. Estrogens induce rapid
activation of diverse signal transduction pathways in time
frames (sec to min) which are inconsistent with the possibility
of being mediated by synthesis of RNA or protein; furthermore,
these effects are usually insensitive to inhibitors of RNA and
protein synthesis [41]. Rapid non-genomic responses to estro-
gens often occur via second messenger cascades, which in turn
originate from signaling complexes located in close proximity
to or at the plasma membrane (for review, see [42]). ERα
directly associates with the p85α regulatory subunit of phos-
phoinositide 3-kinase (PI3K) in a hormone-dependent manner
leading to PI3K/Akt signaling pathway activation inducing
nitric oxide synthase activity [39,40].
Previous work at our laboratory has shown that ERα ac-
tivation induces α1b-adrenoceptor phosphorylation, desensiti-
zation and internalization through a signaling cascade involving
PI3K and PKC δ activities [43]. In addition, we have shown that
PKC stimulation induces LPA1 receptor phosphorylation [44].
In this work, we tested whether E2 could induce heterologous
regulation of LPA1 and further explored the molecular me-
chanisms involved.
2. Materials and methods
2.1. Materials
1-α-Lysophosphatidic acid (oleoyl-sn-glycero-3-phosphate) (LPA), 17-β
estradiol (E2), tetradecanoyl phorbol acetate (TPA), staurosporine, rottlerin, Gö
6976, wortmannin, and protease inhibitors were purchased from Sigma-Aldrich
Chemical Co (St. Louis, MO, USA). LY294002 was obtained from Calbiochem
(La Jolla, CA, USA). ICI 182780 was from Tocris Cookson Inc (Ellisville,
MO, USA). Sepharose-coupled protein Awas from Upstate Biotechnology (Lake
Placid, NY, USA). Nitrocellulose membranes were from Bio-Rad (Hercules, CA,
USA). All primary antibodies were from Santa Cruz Biotechnology (Santa Cruz,CA, USA), except the anti-EGFP, which was generated in our laboratory against
GST-fused EGFP protein. Secondary antibodies were from Zymed (San Francisco,
CA, USA), while chemiluminescence kits were obtained from Pierce (Rockford, IL,
USA). Ham's F12mediumKaighn's modification (F12K) andDulbecco's modified
Eagle's medium (DMEM) without phenol red were from In Vitro (México D.F,
México.), fetal bovine serum, trypsin, antibiotics, reagents used for cell culture, Fura-
2 AM (acetoxy-methyl-ester) and Lipofectamine™ 2000 were obtained from
Invitrogen Life Technologies (Carlsbad, CA, USA). [32P]Pi (8500–9120 Ci/mmol)
was purchased from Perkin Elmer Life Sciences (Wellesley, MA, USA).
2.2. Cell culture
The rat hepatic epithelial cell line, C9, and the human breast cancer cell line,
T47D, were cultured in F12K and RPMI media, respectively. Culture media was
supplemented with 10% fetal bovine serum, 100 μg/ml streptomycin, 100 U/ml
penicillin and 0.25 μg/ml amphotericin B and cells were maintained at 37 °C
under a 95% air, 5% CO2 atmosphere. Growth medium was removed and
replaced with DMEM without phenol red and without fetal bovine serum, 24 h
prior to the experiments.
2.3. Molecular receptor characterization by RT-PCR
Total RNAwas isolated using TRIzol® reagent (Qiagen, Hilden, Germany)
according to themanufacturer's instructions. RT-PCRswere performed in a 50 μl
reaction mixture consisting of 0.1 unit/μl RTAMV (avian myeloblastosis virus),
0.1 unit/μl Tf1 DNA polymerase, reaction buffer AMV/TF1, 1 mM MgSO4,
0.2 mM of each dNTP, 1 μM of each primer and 0.1 μg of total RNA. Samples
were incubated at 48 °C for 45 min, followed by 2 min at 95 °C, and 35 cycles of
30 s at 95 °C, 30 s at 56 °C, and 2min at 72 °C.We employed the primers reported
by Moller et al. [45] and these were purchased from Sigma Chemical Co
(St. Louis, MO, USA).
2.4. Intracellular calcium ([Ca2+]i ) determinations
Cells were loaded with 2.5 μMof the fluorescent Ca2+indicator, Fura-2/AM, in
Krebs–Ringer-HEPES containing 0.05% bovine serum albumin, pH 7.4 for 1 h at
37 °C. Cells were washed three times to eliminate unincorporated dye. Fluo-
rescencemeasurements were carried at 340 nm and 380 nm excitationwavelengths
and 510 nm emission wavelength, with a chopper interval set at 0.5 s using an
AMINCO-Bowman Series 2 luminescence spectrometer (Rochester, NY, USA).
Intracellular calcium ([Ca2+]i) was calculated according to Grynkiewicz et al. [46].
2.5. Expression of LPA1–EGFP in C9 Cells
The full-length cDNA encoding the mouse LPA1 (generously given to us byDr
Kevin Lynch, Department of Pharmacology, University of Virginia, Charlottes-
ville, VA, USA) was amplified and tagged at the C terminus with EGFP as a fusion
protein [43]. C9 cells were stably transfected with the construct utilizing Lipo-
fectamine™ 2000, following the manufacturer's protocol. Clones expressing high
levels of EGFP-tagged LPA receptors were selected by resistance to geneticin
(G418) as well as by fluorescence cell-sorting using FACSCalibur (BD Bio-
sciences) and Cell Quest software (BD Biosciences). As negative control, C9 cells
were also stably transfected with the pEGFP-N1 vector.
2.6. ERα transient expression in C9 cells
C9 cells that stably express LPA1–EGFPwere transfectedwith the human ERα
kindly provided to us by Dr. A.J. Cooney, Baylor College of Medicine (Houston,
TX, USA), using Lipofectamine™ 2000, following the manufacturer's protocol.
2.7. ERα–ECFP construction and transient expression in C9 cells
To generate the ERα fused to enhanced cyan fluorescent protein (ECFP)
construct, the full-length human ERαwas obtained from pT7BhERα plasmid by
PCR amplification kindly provided by Dr. A.J. Cooney, Baylor College of
Medicine (Houston, TX, USA). An XhoI site followed by ERα start nucleotide
Fig. 1. LPA1 and ERa expression in C9 cells. A) expression in C9 cells. A) LPA
receptor subtype gene expression was characterized in C9 wild type cells and
T47D cells by RT-PCR using specific primers. B) Western blot detection of ERα
and ERβ in C9 cells stably expressing LPA1–EGFP (C9), C9 cells transfected
with ERα (C9-ERα) and wild type T47D cells. C) Confocal detection of C9 cells
stably expressing LPA1–EGFP receptors (LPA1–EGFP). EGFP was excited
utilizing the 488 nm line of a krypton/argon laser and fluorescence emitted
detected with a 515–540 nm band pass filter.
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TATGACCATGACCCTCCA-3′. The reverse primer contained a BamHI site after
a stop codon, 5′-GTAATTAGATGGATCCCTTCAGACCGT GGCAGGGA-
AACC-3′. The amplified DNA product was subcloned into pCR® II-TOPO
vector (Invitrogen Life Technologies, Carlsbad, CA, USA) and then re-isolated
with the appropriate enzymes and subcloned into pECFP-C1 vector (CLONTECH
Laboratories, Inc. PaloAlto, CA,USA). The construct was sequenced to verify that
mutations did not occur during PCR amplifications. This receptor was fully
functional as evidenced in estrogen-mediated gene expression experiments (Rocío
García-Becerra and Fernando Larrea, unpublished data). C9 cells that stably
express LPA1–EGFP were transiently transfected with this construct utilizing
Lipofectamine™ 2000, according to the manufacturer's protocol.
2.8. Immunoprecipitation and metabolic labeling of receptors
Cells approaching confluence growing in 35-mm plates were incubated in
phosphate-free Dulbecco's modified Eagle's medium for 1 h and labeled with
[32P]Pi 100 μCi/ml in the same culture media for 4 h at 37 °C. Labeled cells were
stimulated with agents as indicated, and were then washed twice with ice-cold
phosphate-buffered saline and solubilized with 0.5 ml of ice-cold lysis buffer
containing: 100 mM NaCl, 20 mM NaF, 10 mM sodium pyrophosphate, 50 mM
Tris pH 8, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 10 mg/ml deoxycholic
acid (sodium salt) and protease inhibitors (20 μg/ml leupeptin, 20 μg/ml apro-
tinin, 100 μg/ml PMSF, 500 μg/ml bacitracin, 20 μg/ml benzamidine, 20 μg/ml
pepstatin, 50 μg/ml trypsin inhibitor).
Plates were maintained on ice for 1 h and insoluble material was pelleted by
centrifugation at 12000 ×g for 15 min at 4 °C. Supernatants were incubated
overnight at constant agitation at 4 °C with 1:250 anti-EGFP antiserum and
sepharose-coupled protein A. The following day, samples were centrifuged and
the pellets washed three times with buffer WB1 (50 mM Tris HCl, 150 mM
NaCl, 1% Triton X-100, 12 mM deoxycholic acid (sodium salt), pH 7.5), twice
with buffer WB2 (50 mM Tris HCl, 500 mM NaCl, 0.1% Triton X-100, 1.2 mM
deoxycholic acid (sodium salt), pH 7.5) and once with buffer WB3 (50 mM Tris
HCl, 0.1% Triton X-100, 1.2 mM deoxycholic acid (sodium salt), pH 7.5).
Finally the immune complexes were denatured by boiling on loading buffer
(120 mM Tris pH 6.8, 4% SDS, 0.2% glycerol, 5% β-mercaptoethanol, 7 M
Urea, 1 mM DTT and 10 mg/ml bromophenol blue) and subjected to SDS/
PAGE. The gels were dried and receptor phosphorylation was assessed using a
Molecular Dynamics PhosphorImager (Sunnyvale, CA, USA) and the
Imagequant software (Amersham Biosciences; Piscataway, NJ, USA).
2.9. Co-immunoprecipitation studies
LPA1–EGFP receptors were immunoprecipitated as described previously,
with minor modifications. In brief, following treatment with ICI 182780, in-
hibitors and/or E2, cells were washed with ice-cold phosphate-buffered saline
and lysed for 1 h with ice-cold lysis buffer without deoxycholic acid. Lysates
were centrifuged at 12,700 ×g for 15 min and the supernatants were incubated
overnight at 4 °C with the anti-EGFP antiserum and protein A-Sepharose. After
one wash with 50 mM HEPES, 50 mM NaH2PO4, 100 mM NaCl, pH 7.4, and
0.1% Nonident P40, the immune complexes were denatured by boiling in
sodium dodecyl sulfate-sample buffer containing 5% β-mercaptoethanol, and
subjected to 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Proteins were electrotransferred to nitrocellulose membranes and immunoblot-
ting was performed. Incubation with PKC α-or PKC ɛ-selective antibodies was
performed for 12 h at 4 °C and with the secondary antibody for 30 min at room
temperature. Super signal-enhanced chemiluminescence kits were used, ex-
posing membranes to X-Omat X-ray films; all co-immunoprecipitations were
assessed by densitometric analysis.
2.10. Western blot assays
Cells were washed with ice-cold phosphate-buffered saline and lysed for 1 h
on ice as previously described. Lysates were centrifuged at 12,700 ×g for 15 min
and proteins in supernatants were quantified. In all immunoblots, equal amounts
of protein (70 μg) were separated by electrophoresis on 10% SDS-PAGE.
Proteins were electrotransferred to nitrocellulose membranes and immunoblot-ting was performed. Incubation with ERα or ERβ selective antibodies or anti-
EGFP serum was conducted for 12 h at 4 °C and with the secondary antibody for
30 min at room temperature. Super signal-enhanced chemiluminescence kits
were used exposing the membranes to X-Omat X-ray films.
2.11. Confocal microscopy
Confocal images were obtained using a OLYMPUS Fluoview FV 1000 con-
focal system (Olympous corporation, Shinjuku Monolith, Tokyo, Japan) attached/
interfaced to an OLYMPUS IX81 inverted light microscope with a 40× glycerol-
immersion objective. EGFP was excited using the 488 nm line of a krypton/argon
laser and the fluorescence emitted was detected with a 515–540 nm band pass filter.
ECFP was excited employing the 405 nm line of a krypton/argon laser and the
fluorescence emitted was detected with a 425–476 nm band pass filter. All images
were obtained using numeric aperture 1.3 and the same laser percentage, iris
aperture and gain. Operating the laser at a low power setting (97–99% attenuation)
substantially reduced photobleaching and photodamage. Confocal images were
viewed, processed and converted to TIFF format with the software FV10-ASW
(Olympus Corporation, Tokyo, Japan). Assays were carried out with cells growing
on a tissue culture dish (35-mm) with cover glass bottom (23-mm) plates. When E2
or ICI 182780 was added, the solution was pipetted directly into the dishes, while
pictures were taken simultaneously.
2.12. Statistical analysis
All data were analyzed and plotted utilizing GraphPad Prism version 4.00
for Windows software, (GraphPad Software, San Diego, CA, USA). Statistical
Fig. 2. Effect of E2 and LPA on [Ca
2+]i in T47D and C9 wild type cells. T47D
cells (A, upper panel) or C9wild type cells (B, lower panel). Intracellular calcium
in the absence of stimulus (B) or challenged with 1 μM LPA without pre-
incubation (LPA) or pre-incubated with 1 μM E2 (for 5 min) (+E2); 2 μM ICI
182780 (20 min) and 1 μME2 (for 5 min) (+ICI+E2) or with 1 mMTPA (+TPA)
before challenging with LPA. Plotted are the means ±S.E.M. of 5 experiments.
⁎P≤0.05 vs. all groups. ⁎⁎p≤0.05 vs. B. ⁎⁎⁎p≤0.05 vs. all groups except B.
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ferroni's posttest. A value of pb0.05 was considered statistically significant, as
stated in the figure legends.Fig. 3. Effect of different concentrations of lysophosphatidic acid (LPA) and 17-β es
expressing LPA1–EGFP and transiently expressing ERαwere labeled with fura-2AM
(5 min)+LPA (center) or 1 μM E2 (right) are shown. B) Cells were challenged with
concentrations of E2 for 5 min and then challenged with 1 μM LPA. Plotted are me3. Results
3.1. ERα and LPA1 expression in C9 and T47D cells
The lack of subtype-selective LPA receptor antibodies that
might reliably determine their expression in cells limited us to
determine their gene expression byRT-PCRusing specific primers
for each subtype [45]. As shown in Fig. 1, C9 wild type cells
express LPA1, and LPA2 receptor genes [44] and T47D cells
express those for LPA1, LPA2 and LPA3 receptors (Fig. 1A). C9
cells barely express ERα (Fig. 1B) and the expression of ERβ is
either very low or absent since it was not clearly detected by
Western blot analysis; T47D cells express both receptors (ERα:
ERβ ratio approximately 9:1) [47] (Fig. 1B).We usedC9 cells that
stably express human LPA1 fused to EGFP (LPA1–EGFP) and
transfected themwith human ERα. Western blotting and confocal
microscopy evidenced transient expression of ERα (Fig. 1B) and
stable expression of LPA1–EGFP (Fig. 1C) respectively.
3.2. Effect of 17-β estradiol on LPA1 function and PKC and
PI3K roles
The effect of LPA1 was next examined. In T47D cells that
abundantly expressed ERα, LPA induced an increase in [Ca2+]i,
and cell-treatment with 17-β estradiol (E2) for 5 min decreased the
magnitude of the action of LPA (Fig. 2A); the effect of E2 was
abolished if cells were pre-incubated for 20 min with 2 μM ICI
182780, a selective estrogen antagonist (Fig. 2A). TPAwas used as
positive control of LPA1 receptor desensitization (Fig. 2A and B).
In C9 wild type cells, that barely express ERα, LPA also induced
an increase in [Ca2+]i, but in contrast to that observed with T47Dtradiol (E2) on intracellular free calcium concentration ([Ca
2+]i). C9 cells stably
. A) Representative tracings from cells challenged with 1 μMLPA (left), 1 μME2
different concentrations of LPA. C) Cells were pre-incubated with the indicated
ans±S.E.M. of 5 experiments performed with different cell preparations.
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C9 cells, that stably express LPA1–EGFP and transiently express
ERα, LPA increased intracellular calcium (Fig. 3A) with an EC50
value of 30 nM (Fig. 3B); cell incubation with E2, for 5 min,
decreased the effect of LPA, in a concentration-dependent fashion
(Fig. 3C). Incubation with E2 diminished (∼30%) the increase in
[Ca2+]i induced by LPA (Fig. 3C and 4A) with an EC50 value of
5 nM. This effect of E2 was abolished in cells pre-incubated
(20 min) with the selective estrogen antagonist ICI 182780,
(Fig. 4A). ICI 182780 neither induced any detectable change in
basal [Ca2+]i by itself nor altered the effect of LPA (Fig. 4A).
PKC and PI3K are key enzymes in heterologous desensitiza-
tion and receptor phosphorylation [33,46–48]. To determine their
role in E2-induced LPA1 desensitization, different PKC and PI3K
inhibitorswere tested. As shown in Fig. 4B,wortmannin (100 nM)
and LY294002 (1 μM), blocked E2 action on LPA-mediated
increase in [Ca2+]i. Similarly, staurosporine a general inhibitor of
PKC isoenzymes and Gö 6976, a selective PKC α inhibitor,
abolished E2-mediated modulation of LPA action (Fig. 4B). In a
previous work [43], we found that rottlerin a selective inhibitor of
PKC δ, abolished the effect of E2 on α1b-adrenergic mediated
actions. Interestingly, rottlerin did not affect the desensitization of
LPA1 receptor, induced byE2 (Fig. 4B), suggesting that PKC δ didFig. 4. Effect of E2 and LPA on [Ca
2+]i. Roles of PI3K and PKC. A) Cells were
challenged with 1 μM LPA; 1 μM E2; E2 (5 min)+LPA; 2 μM ICI 182780; ICI
182780 (20 min)+E2+LPA and ICI 182780 (20 min)+LPA. B) Cells were
challenged with 1 μM LPA; 1 μM E2 (5 min)+LPA; PKC general inhibitor:
staurosporine (ST) 1 μM+E2+LPA; PKCα inhibitor: Gö 6976 (Go) 1 μM+E2+
LPA; PKC δ inhibitor: rottlerin (Rott) 100 nM+E2+LPA; PI3K inhibitors:
LY294002 (LY) 1 μM or wortmannin (W) (100 nM)+E2+LPA. Inhibitors were
added 20 min before LPA or E2. Plotted are means±S.E.M. of 5 experiments.
⁎P≤0.05 vs. all groups. ⁎⁎p≤0.05 vs. all groups except Rott.
Fig. 5. Phosphorylation of LPA1 induced by E2, roles of PI3K and PKC. C9 stably
expressing LPA1–EGFP were metabolically labeled with [
32P]Pi. Cells were
treated with E2 for 5 min or pre-incubated 30 min prior to E2 treatment with A)
2 μM ICI 182780 or PKC inhibitors or B) PI3K inhibitors. All inhibitor con-
centrations were employed as indicated in Fig. 3. Plotted are means±S.E.M. of 5
experiments. A representative autoradiograph is shown. ⁎P≤0.05 vs. all groups.
⁎⁎p≤0.05 vs. all groups except Rott.not play a major role. None of these inhibitors alter the LPA-
induced increase in [Ca2+]i (supplemental Fig. 1).
3.3. E2 induces LPA1 phosphorylation; PI3K and PKC
participate in this event
We next examined the pathway through which E2 induces
LPA1 receptor phosphorylation. Again TPAwas used as a positive
control (Fig. 5A). As shown in Fig. 5 (A and B), 1 μM E2
increased this (∼2-fold) and the estrogen receptor antagonist, ICI
182780, blocked this effect (Fig. 5A). Inhibitors such as
staurosporine, Gö 6976, rottlerin, wortmannin and LY294002
were utilized to determine the roles of PKC and/or PI3K. As
shown in Fig. 5A and B these inhibitors, with the exception of
rottlerin, abolished E2-induced LPA1 receptor phosphorylation,
suggesting that PKC α, but not δ, plays a role in this effect.
3.4. PKCα associates with LPA1 in a dynamic fashion
To obtain further insight into themolecular events involved in
these effects, associations of LPA1 with PKC α, βI, βII, δ, ɛ and
ζ were studied by co-immunoprecipitation. The results showed
Fig. 6. Effect of E2 on co-immunoprecipitation of LPA1 with PKC a and PKC and
PKC ɛ. C9 cells stably expressingLPA1–EGFPwere treatedwith 1μME2 for 5min
or pre-incubated prior to E2 treatment with 2 μM ICI 182780 or PKC inhibitors
(concentrations as in Fig. 3) for 30 min. LPA1 receptors were immunoprecipitated
and samples were subjected to electrophoresis andWestern blot analysis for PKC α
(A, upper panel) or PKC ɛ (B, lower panel); IPP, samples immunoprecipitated with
PKC isoform-selective antibodies. Representative Western blots are shown. Data
are presented as % of basal. Plotted are means±S.E.M. of 5 experiments performed
using different cell preparations. ⁎P≤0.05 vs. all groups.
Fig. 7. ERαa–ECFP transfection and LPA1–EGFP localization. C9 cells stably
expressing LPA1–EGFP were transfected with ERα–ECFP. A) ERα–ECFP
expression in C9 cells. B) ER α–ECFP (left). LPA1–EGFP (middle) was mainly
localized at the plasma membrane and to a lesser extent in intracellular vesicles.
EGFP was excited using the 488 nm line of a krypton/argon laser and the
fluorescence emitted was detected with a 515–540 nm band pass filter. ECFP
was excited using the 405 nm line of a krypton/argon laser and the fluorescence
emitted was detected with a 425–476 nm band pass filter.
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forms under non-stimulated conditions (data not shown).
Interestingly, isoformswhose co-immunoprecipitation increased
in response to E2 were PKC α (Fig. 6A) and PKC ɛ (Fig. 6B).
Treatment with ICI 182780 diminished this effect (Fig. 6A).
Staurosporine and Gö 6976 (Fig. 6A) blocked the association of
PKC αwith LPA1.Western blotting of immunoprecipitated LPA1
receptors was employed as loading control in co-immunopreci-
pitation experiments; the amount of immunoprecipitated receptor
was essentially constant under all conditions tested (supplemental
Fig. 2).
3.5. Subcellular localization of LPA1 receptors
Current evidence indicates that GPCR phosphorylation is fre-
quently associated with receptor internalization [27,29]. There-fore, our next aim comprised investigatingwhether E2 could affect
the subcellular localization of LPA1. To study this, we used C9
LPA1–EGFP cells transfected with ERα–ECFP. Transient ex-
pression of ERα–ECFP was corroborated by confocal micro-
scopy (Fig. 7A and B). Fig. 7B shows that LPA1–EGFP is located
at the plasma membrane and in intracellular vesicles. E2 induced
internalization of LPA1 receptors (Fig. 8A) and pre-treatment
with ICI 182780 inhibited this effect (Fig. 8B). The process was
visualized in real time showing a relatively rapid effect of E2
(5 min) (supplemental Fig. 3 (movie)). To demonstrate that ERα–
ECFP exerted the same effect on LPA1 function, we tested the
[Ca2+]i response in cells C9 stably expressing LPA1–EGFP. LPA
clearly increased [Ca2+]i, E2 decreased this effect and ICI 182780
inhibited the processes in a similar fashion to that observed in cells
transfected with wild type ERα (Fig. 9).
4. Discussion
Phosphorylation and heterologous desensitization of LPA1
receptors have been previously observed in response to agents
acting though membrane receptors, and PKC plays a cardinal
role in these effects [44]. Similarly, PKC mediates desensiti-
zation of α1b-adrenoreceptors [48–50]. In the present paper,
phosphorylation and heterologous desensitization of LPA1 re-
ceptor by activation of an intracellular receptor are shown.
4.1. Estrogen modulates LPA1 receptor function: roles of PI3K
and PKC
Defining the manner in which estrogens might function is a
complicated task, particularly because they bind to and activate
two different intracellular nuclear receptors and may also have
Fig. 9. [Ca2+]i determination in C9 cells stably expressing LPA1–EGFP and
transfected with ERa–ECFP. Cells were pre-incubated in the absence of any
agent or with 1–ECFP. Cells were pre-incubated in the absence of any agent or
with 1 μM E2 for 5 min. After this pre-incubation cells were challenged with
1 μM LPA. Plotted are means±S.E.M. of 3 experiments. Data are present as %
of basal [Ca2+]i. ⁎P≤0.05 vs. all groups.
Fig. 8. Effect of E2 on LPA1 internalization. Cells were pre-incubated with no
any agent (A, upper panels) or with 2 mM ICI 182780 for 30 min (B, lower
panels) and further incubated for 5 min with no agent (C) or with 1 μM E2.
EGFPwas excited using the 488 nm line of a krypton/argon laser and the emitted
fluorescence was detected with a 515–540 nm band pass filter. Images are
representative of 3 experiments using different cell preparations.
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as GPR30) [51,52]. Our present data clearly show participation of
ERα in E2-modulation of LPA1 receptor function. In C9wild type
cells that poorly express ERα (Fig. 1B), E2 does not modify the
increase in [Ca2+]i induced by LPA; it was not until ERα were
overexpressed by transfection, that the effect of estrogen was
evidenced (Figs. 2B, 3A and B). T47D cells that abundantly
exhibit ERα (Fig. 1B) show desensitization of LPA receptors in
response to E2 treatment (Fig. 2A). The hardly detectable pre-
sence of ERβ in C9 and its low expression in T47D cells (Fig. 1B)
further suggest that E2 effects were mediated through ERα.
Nevertheless, we cannot completely rule out the participation of
these intracellular receptors or that of GPCRs in these actions.
Modulation of membrane receptor function by ERα has been
documented in different studies [43,53,54]. Our previous work
showed that α1b-adrenoreceptors are regulated by ERα [43] by
inducing desensitization, phosphorylation, and internalization.
Kelly and coworkers [53,54] have shown that ERs can modu-
late the action of other GPCRs, such as μ-opiod and GABA-B
receptors, by uncoupling these to the rectifying K+ channels
through protein kinase A and PKC activities. A recent study
demonstrated effects of E2 through transactivation of EGF re-
ceptor via stimulation of sphingosine kinase 1 activity, release
of sphingosine 1-phosphate and autocrine action on SP1 recep-
tors [55]. Our data shows that E2, through ERα, induces LPA1
phosphorylation, desensitization and internalization in non-
genomic rapid fashion.
Different studies indicate that the fast effects of estrogens are
mediated by a subpopulation of conventional plasmamembrane-
associated ER [56,57]. ERα fused to the green fluorescentprotein has been used to visualize ERα in the plasma membrane
of neurites [57]; it is possible that a small population of this
receptor, in proximity to the plasma membrane, might partici-
pate in the rapid effects of E2 presented herein.
Association of ERα with the PI3K p85α regulatory subunit
resulting in PI3K/Akt signaling pathway activation is among the
non-genomic mechanisms of action of estrogens [40–42]. We
used two blockers of PI3K with different mechanisms of action;
wortmannin, a potent and selective non-competitive inhibitor
[58] and LY 294002, a blocker that competes at the ATP binding
site of this kinase [59]. These inhibitors, clearly and consis-
tently, blocked E2-induced LPA1 receptor desensitization and
phosphorylation (Figs. 4B and 5B), which strongly suggested a
role of PI3K in these effects.
PI3K regulates PKC activity through the synthesis of 3-
phosphorylated phosphoinositides, which directly interact with
PKC. In addition, they are important regulators of phosphoinosi-
tide-dependent protein kinase 1 (PDK-1), which phosphorylates
the activation loop of some PKC isoforms [60]. In our previous
work, it was shown that ERα associates with and stimulates PI3K
activity, leading to PKC δ activation, which phosphorylates and
desensitizes α1b-ARs [43]. In this work inhibitors of PKC and
PI3K blocked E2 effects on LPA1 receptor desensitization and
phosphorylation, suggesting that they act sequentially and not in
parallel. It is very likely that PI3K activation may precede that
of PKC, because phorbol esters induce marked LPA1 receptor
phosphorylation even in the presence of PI3K inhibitors. Nev-
ertheless, it should be mentioned that PI3K actions, probably
extend beyond inducing PKC activation. PI3K is a dual kinase
capable of phosphorylating phosphoinositides and proteins and it
was shown recently that it plays key roles in β2-AR endocytosis
[61]. Interestingly, PI3K serine/threonine protein kinase activity
phosphorylates tropomyosin, this action appearing to be critical
for receptor internalization [61]. However, it remains to be shown
whether a similar role is played for LPA1 receptor internalization.
PKC activation blocks LPA1 actions by inducing its phos-
phorylation [44]. PKC α association with LPA1 was consistent
with the inhibitory ability of staurosporine and Gö 6976 over
LPA1 phosphorylation and desensitization (Fig. 6A). It has been
known for some time that formation of protein complexes
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receptors with intrinsic tyrosine kinase activity [62]. At present, it
is accepted that this is a more general process, and not solely
limited to these receptors [63]. Formation of multimolecular
complexes has been shown to participate in the regulation of
GPCR, including among others, α1b adrenoceptors [43] and
angiotensin AT1 receptors [64]. The term signalplex has been
coined to define these protein–protein multimolecular complexes
involved in signaling and receptor modulation [65]. Protein–pro-
tein interactions are defining new connections among signaling
pathways, these are potentially capable of controlling spatial and
temporal cell responses [63–66]. The data presented herein
suggest that the association of PKC α and LPA1 receptors may be
part of a signalplex involved in LPA1 modulation by estrogens. It
is currently unknown whether such a possible interaction may
occur directly or via anchoring or scaffolding proteins.
In the present work, the PKC isoforms α, βI, δ and ɛ co-
immunoprecipitated with LPA1 under non-stimulated conditions;
nonetheless, treatment with E2 only increased the association of
PKC α and ɛ with the LPA1 receptor. Our data showed that
association of PKC α with LPA1 receptors after E2 treatment,
correlated with desensitization and phosphorylation of these
receptors; it appears likely that PKC α increases its association
with LPA1 receptors, in response to E2, to induce phosphorylation
and consequently desensitization. Notwithstanding this, the role
of PKC ɛ association with LPA1 receptors remains uncertain.
The existence of five LPA receptor subtypes suggests that
these might have different properties in their action and/or re-
gulation; additionally, it is possible that combinatorial functions
or synergisms may exist in cells expressing more than one
subtype. LPA receptor phosphorylation and desensitization
might have physiological importance; given that receptor's
persistent activity could participate in the genesis of pathological
conditions. Information concerning LPA1 receptor tissue ex-
pression and regulation appears to be important in establishing
differences among receptor properties and functions.
The tissue distribution and regulation of LPA receptor sub-
types is beginning to be unraveled. To the best of our knowledge
no previous information regarding estrogen-mediated regula-
tion of LPA receptor function has been reported. Considering
the plethora of effects in which these are involved [1,3–5], it is
likely that modulation of their expression and function by es-
trogens could play roles in physiological or pathological con-
ditions, particularly in estrogen-responsive tissues. For instance,
it has been shown that LPA plays a pivotal role in embryo
implantation via LPA3 receptors [67], and additional evidence
indicates that estrogens and progesterone modulate their ex-
pression in the uterus [68]. On the pathological side, it is known
that serum LPA is elevated in patients suffering from ovarian
cancer and it has been suggested that it might serve as a bio-
marker for the disease [69,70]. This type of cancer cells ex-
presses LPA1 and LPA2 receptors [71]. Therapeutic intervention
at the levels of LPA generation, LPA receptor expression,
signaling, and regulation, appears promising for patients suf-
fering from this disease. We think that our data showing that E2
through ERα induces LPA1 receptor phosphorylation, desensi-
tization and internalization, with the participation of PI3K andPKC, contribute to understanding the tight interaction between
signaling pathways in health and disease.
In summary, the present data show that E2 through ERα
induces LPA1 receptor phosphorylation, desensitization, and
internalization, and that PI3K and PKC α play a cardinal role in
these actions.
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